Flinton Capital Management LLC boosted its stake in Humana Inc (NYSE:HUM) by 40.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 57,680 shares of the insurance provider’s stock after acquiring an additional 16,640 shares during the quarter. Flinton Capital Management LLC’s holdings in Humana were worth $14,309,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in HUM. Fieldpoint Private Securities LLC purchased a new position in Humana in the 3rd quarter valued at $115,000. American Beacon Advisors Inc. purchased a new position in shares of Humana during the 4th quarter worth $122,000. ClariVest Asset Management LLC purchased a new position in shares of Humana during the 3rd quarter worth $144,000. YorkBridge Wealth Partners LLC raised its holdings in shares of Humana by 99.0% during the 4th quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock worth $159,000 after acquiring an additional 297 shares during the period. Finally, Daiwa SB Investments Ltd. raised its holdings in shares of Humana by 44.9% during the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after acquiring an additional 220 shares during the period. 96.36% of the stock is currently owned by hedge funds and other institutional investors.
In other news, SVP Cynthia H. Zipperle sold 1,196 shares of the company’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $273.33, for a total value of $326,902.68. Following the sale, the senior vice president now directly owns 7,771 shares in the company, valued at $2,124,047.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bruce D. Broussard sold 14,075 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $274.32, for a total value of $3,861,054.00. Following the completion of the sale, the chief executive officer now owns 113,896 shares in the company, valued at $31,243,950.72. The disclosure for this sale can be found here. Insiders sold 33,339 shares of company stock worth $9,081,201 in the last three months. 0.60% of the stock is owned by corporate insiders.
A number of analysts recently issued reports on HUM shares. Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. JPMorgan Chase & Co. lifted their target price on Humana from $253.00 to $271.00 and gave the company a “neutral” rating in a research report on Monday, February 12th. Deutsche Bank lifted their target price on Humana from $259.00 to $270.00 and gave the company a “hold” rating in a research report on Friday, February 9th. Jefferies Group raised Humana from a “hold” rating to a “buy” rating and set a $221.00 price objective for the company in a research report on Friday, January 12th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $230.00 price objective on shares of Humana in a research report on Tuesday, December 5th. Eight analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Humana currently has an average rating of “Buy” and a consensus target price of $270.47.
Humana Inc (NYSE:HUM) traded up $5.49 during trading on Tuesday, hitting $275.47. The stock had a trading volume of 534,699 shares, compared to its average volume of 1,109,834. Humana Inc has a twelve month low of $203.48 and a twelve month high of $293.35. The stock has a market capitalization of $37,550.64, a PE ratio of 16.19, a PEG ratio of 1.48 and a beta of 0.95. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.85.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The firm had revenue of $13.19 billion for the quarter, compared to analyst estimates of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. Humana’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.34 earnings per share. sell-side analysts expect that Humana Inc will post 13.81 EPS for the current fiscal year.
Humana declared that its board has authorized a stock buyback program on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to purchase shares of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s management believes its stock is undervalued.
The company also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be issued a $0.50 dividend. This is a positive change from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 annualized dividend and a yield of 0.73%. Humana’s dividend payout ratio is 9.59%.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.